More pressure on pulmonary hypertension: Table. 1—

Humbert, Marc

doi:10.1183/09059180.00011101

Cited by 5 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the BMPR2 mutation has a penetrance of only ,10-20%. This suggests that this genetic predisposition increases susceptibility to PAH, but that additional risk factors need to be present to induce pulmonary vascular dysfunction at the level of endothelial cells and smooth muscle cells [12]. The role of additional risk factors is highlighted by the recently updated clinical classification of PAH [1], which emphasises that PAH can be induced by various factors, including drugs or toxins.…”

Section: Risk Factorsmentioning

confidence: 99%

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology

Humbert¹

2010

Eur Respir Rev

Self Cite

143

104

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two of the key subgroups of pulmonary hypertension. They are characterised by different risk factors. PAH can be associated with mutations in the gene encoding bone morphogenetic protein receptor type II (BMPR2), HIV infection, congenital heart disease, connective tissue disease (such as systemic sclerosis), and exposure to particular drugs and toxins including fenfluramine derivatives. In contrast, CTEPH can be associated with antiphospholipid antibodies, splenectomy and the presence of a ventriculo-atrial shunt or an infected pacemaker.The first-line therapies used to treat PAH and CTEPH also differ. While medical therapy tends to be used for patients with PAH, pulmonary endarterectomy is the treatment of choice for patients with CTEPH.However, there are possible common mechanisms behind the two diseases, including endothelial cell dysfunction and distal pulmonary artery remodelling. Further research into these similarities is needed to assist the development of targeted pharmacological therapies for patients with inoperable CTEPH and patients who have persistent pulmonary hypertension after endarterectomy.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology

Humbert¹

2010

Eur Respir Rev

Self Cite

143

104

View full text Add to dashboard Cite

show abstract

“…In this new era for the ERR, our aim was to further enhance scientific content and to form and develop strong links with the flagship publication of the European Respiratory Society (ERS), the European Respiratory Journal (ERJ), in order to establish the ERR as a companion to the ERJ, without providing competition with the other ERS publications (European Respiratory Monograph and Breathe) [1]. In 2009, the format of the ERR was significantly restructured and the important decision was made to publish sponsored content, as well as spontaneously submitted original material [2,3]. Importantly, all the articles comprising this new format for the ERR have undergone peer review so that the highest scientific standards are maintained.…”

mentioning

confidence: 99%

You say goodbye, and I say hello!

Humbert¹

2012

Eur Respir Rev

Self Cite

View full text Add to dashboard Cite

“…Each issue will start with a number of editorials related to the theme of the month, usually commenting on recent cutting-edge research developments in areas related to the topic in question. Besides the present editorial, another commentary will also introduce the first theme, that of pulmonary hypertension [1]. In addition to this, an editorial written by SHOVLIN et al [2] on the difficult question of embolisation of pulmonary arteriovenous malformations in pulmonary hypertensive patients is also included.…”

mentioning

confidence: 99%